1. Abush H, Akirav I. Cannabinoids Ameliorate Impairments Induced by Chronic Stress to Synaptic Plasticity and Short-Term Memory. Neuropsychopharmacology. 2013. 38: 1521-34
2. Aso E, Juves S, Maldonado R, Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A beta PP/PS1 mice. J Alzheimers Dis. 2013. 35: 847-58
3. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000. 404: 84-7
4. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa AJ. Safety and side effects of cannabidiol: A Cannabis sativa constituent. Curr Drug Saf. 2011. 6: 237-49
5. Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011. 36: 1219-26
6. Bih CI, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015. 12: 699-730
7. Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pathological overproduction: The bad side of adenosine. Br J Pharmacol. 2017. 174: 1945-60
8. Bredt DS, Furey ML, Chen G, Lovenberg T, Drevets WC, Manji HK. Translating depression biomarkers for improved targeted therapies. Neurosci Biobehav Rev. 2015. 59: 1-15
9. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol. 2007. 152: 567-75
10. Campos AC, Fogaça MV, Scarante FF, Joca SRL, Sales AJ, Gomes FV. Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Front Pharmacol. 2017. 8: 269-
11. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012. 367: 3364-78
12. Camposa AC, Fogac MV, Sonegoa AB, Guimarãesa FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016. 112: 119-27
13. Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, Velasco G. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006. 66: 6748-55
14. Carracedo A, Lorente M, Egia A, Blazquez C, Garcia S, Giroux V. The stress-regulated protein p8 mediates cannabinoid-induced ptosis of tumor cells. Cancer Cell. 2006. 9: 301-12
15. Cassan C, Liblau RS. Immune tolerance and control of CNS autoimmunity: From animal models to MS patients. J Neurochem. 2007. 100: 883-92
16. Castillo A, Tolóna MR, Fernández-Ruizb , J , Romeroa J, Martinez-Orgadoa J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiol Dis. 2010. 37: 434-40
17. Castren E. Neuronal network plasticity and recovery from depression. JAMA Psychiatry. 2013. 70: 983-9
18. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain. 2007. 130: 2543-53
19. Chen RQ, Zhang J, Fan N, Teng ZQ, Wu Y, Yang HW. Delta(9)-THC-caused synaptic and memory impairments are mediated through COX-2 signaling. Cell. 2013. 155: 1154-65
20. Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol. 1982. 83: 293-8
21. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav. 1991. 40: 701-8
22. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 1997. 38: 44-8
23. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci. 1986. 30: 277-82
24. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004. 29: 417-26
25. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel G, Gagliardi . Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980. 21: 175-85
26. De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro-apoptotic effects and underlying mechanisms. Br J Pharmacol. 2013. 168: 79-102
27. Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR, DeLorenzo RJ. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol. 2007. 558: 52-9
28. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014. 55: 791-802
29. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J. Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. Lancet Neurol. 2016. 15: 270-8
30. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017. 376: 2011-20
31. Esposito G, De Filippis D, Steardo L, Scuderi C, Savani C, Cuomo V. CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci Lett. 2006. 404: 342-6
32. Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1ß and iNOS expression. Br J Pharmacol. 2007. 151: 1272-9
33. Esposito G, Scuderi C, Valenza M, Togna GI, Latina V. Cannabidiol reduces ab-induced neuroinflammation and promotes hippocampal neurogenesis through PPARc involvement. PLoS One. 2011. 6: e28668-
34. Fellermeier M, Eisenreich W, Bacher A, Zenk MH. Biosynthesis of cannabinoids. Eur J Biochem. 2001. 268: 1596-604
35. Fernandez-Ruiz J, Moreno-Martet M, Rodriguez-Cueto C, Palomo-Garo C, Gomez-Canas M, Valdeolivas S. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol. 2011. 163: 1365-78
36. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: A multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006. 17: 636-41
37. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003. 83: 1017-66
38. Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2015. 373: 1048-58
39. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R. Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009. 66: 95-105
40. Gaoni Y, Mechoulam R. Isolation structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964. 86: 1646-7
41. Garcia-Arencibia M, Gonzalez S, de Lago E, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007. 1134: 162-70
42. Glass M, Dragunow M, Faull RL.editors. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997. 77: 299-318
43. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014. 3: CD009270-
44. Gowran A, Noonan J, Campbell VA. The multiplicity of action of cannabinoids: Implications for treating neurodegeneration. CNS Neurosci Ther. 2011. 17: 637-44
45. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: Anecdotal evidence and the need for clinical research. J Psychoactive Drugs. 1998. 30: 171-7
46. Guo J, Ikeda SR. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Mol Pharmacol. 2004. 65: 665-74
47. Last accessed on 2018 Jan 29. Available from: https://www.gwpharm.com/about-us/news/gw-pharmaceuticals-achieves-positive-results-phase-2-proof-concept-study-glioma/.
48. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998. 95: 8268-73
49. Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: A unified critical inventory. Nat Prod Rep. 2016. 33: 1357-
50. Hermann D, Schneider M. Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: A critical review. Curr Pharm Des. 2012. 18: 4897-905
51. Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther. 2012. 133: 79-97
52. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review. JAMA. 2015. 313: 2474-83
53. Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp Ther. 2000. 294: 27-32
54. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002. 54: 161-202
55. Huntley A. A review of the evidence for efficacy of complementary and alternative medicines in MS. Int MS J. 2006. 13: 5-12
56. Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: Potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014. 5: 1131-41
57. Iffland K, Grotenhermen F.editors. European Industrial Hemp Association (EIHA) review on: Safety and Side Effects of Cannabidiol– A review of clinical data and relevant animal studies. Germany: Hürth; 2016. p.
58. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007. 23: 17-24
59. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive componentpCannabis sativa, on ß-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004. 89: 134-41
60. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: A promising drug for neurodegenerative disorders?. CNS Neurosci Ther. 2009. 15: 65-75
61. Jones NA, Glyn SE, Akiyama S, Hill TDM, Hill AJ, Weston SE. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure-Eur J Epilepsy. 2012. 21: 344-52
62. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010. 332: 569-77
63. Kapur A, Zhao PW, Sharir H, Bai YS, Caron MG, Barak LS. A typical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem. 2009. 284: 29817-27
64. Karler R, Calder LD, Turkanis SA. Prolonged CNS hyperexcitability in mice after a single exposure to delta-9-tetrahydrocannabinol. Neuropharmacology. 1989. 25: 441-6
65. Kim D, Thayer SA. Cannabinoids Inhibit the Formation of New Synapses between Hippocampal Neurons in Culture. J Neurosci. 2001. 21: RC146-
66. Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders, Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014. 82: 1556-63
67. Kreitzer AC, Malenka RC. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci. 2005. 25: 10537-45
68. Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, Manzoni OJ. Molecular Components and Functions of the Endocannabinoid System in Mouse Prefrontal Cortex. PLoS One. 2007. 2: e709-
69. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012. 2: e94-
70. Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016. 96: 1593-659
71. Ligresti A, Schiano Moriello A, Starowicz K, Matias I, Pisanti S, De Petrocellis L. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006. 318: 1375-87
72. Loria F, Petrosino S, Hernangómez M, Mestre M, Spagnolo A, Correa F. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis. 2010. 37: 166-76
73. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005. 95: 437-45
74. Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci. 2006. 63: 2057-66
75. Mato S, Sanchez-Gomez MV, Matute C. Cannabidiol induces intracellular calcium elevation and cytotoxicity in oligodendrocytes. Glia. 2010. 58: 1739-47
76. McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat. 2011. 129: 37-47
77. McHugh D, Page J, Dunn E, Bradshaw HB. Delta(9)-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 2012. 165: 2414-24
78. Mecha M, Feliú A, Carrillo-Salinas F, Guaza CHandbook of Cannabis and Related Pathologies. Elsevier; 2017. p. 893-904
79. Mecha M, Torrao AS, Mestre L, Carrillo-Salinas FJ, Mechoulam R, Guaza C. Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Dis. 2012. 3: e331-
80. Mechoulam R, Braun P, Gaoni YA. Stereospecific synthesis of (-)-delta 1- and (-)-delta 1(6)-tetrahydrocannabinols. J Am Chem Soc. 1967. 89: 4552-4
81. Mechoulam R, Shvo Y, Hashish I. The structure of cannabidiol. Tetrahedron. 1963. 19: 2073-8
82. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002. 34: 13-25
83. Oakley JC, Kalume F, Catterall WA. Insights into pathophysiology and therapy from a mouse model of Dravet syndrome. Epilepsia. 2011. 52: 59-61
84. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006. 27: 73-100
85. Pertwee R. Pharmacological and therapeutic targets for Δ9 tetrahydrocannabinol and cannabidiol. Euphytica. 2004. 140: 73-
86. Pertwee RG. Pharmacology of Cannabinoid CB1 and CB2 Receptors. Pharmacol Ther. 1997. 74: 129-80
87. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009. 156: 397-411
88. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol. 2008. 153: 199-215
89. Pettit DAD, Harrison MP, Olson JM, Spencer RF, Cabral GA. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J. Neurosci Res. 1998. 51: 391-402
90. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: Actions on signals involved in angiogenesis and metastasis. FASEB J. 2003. 17: 1771-3
91. Rabinak CA, Angstadt M, Sripada CS, Abelson JL, Liberzon I, Milad MR. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology. 2013. 64: 396-402
92. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005. 25: 1904-13
93. Rea K, Roche M, Finn DP. Supraspinal modulation of pain by cannabinoids: The role of GABA and glutamate. Br J Pharmacol. 2007. 152: 633-48
94. Rog DJ, Nurmikko TJ, Young CA. Oromucosal, Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007. 29: 2068-79
95. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005. 65: 812-9
96. Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014. 34: 587-91
97. Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010. 51: 768-72
98. Ronesi J, Lovinger DM. Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. J Physiol. 2005. 562: 245-56
99. Sagredo O, Gonzalez S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Glia. 2009. 57: 1154-67
100. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernandez-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci. 2007. 26: 843-51
101. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Egia A, Lorente M. TRB3 links ER stress to autophagy in cannabinoid anti-tumoral action. Autophagy. 2009. 5: 1048-9
102. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, Egia A. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest. 2009. 119: 1359-72
103. Sano K, Mishima K, Koushi E, Orito K, Egashira N, Irie K. Delta(9)- tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Neuroscience. 2008. 151: 320-8
104. Schultes RE. Man and marijuana. Nat Hist. 1973. 82: 59-
105. Schultes RE. Hallucinogens of Plant Origin.Science. 1969. 163: 245-54
106. Schurman LD, Lichtman AH. Endocannabinoids: A promising impact for traumatic brain injury. Front Pharmacol. 2017. 8: 69-
107. Shah A, Carreno FR, Frazer A. Therapeutic modalities for treatment resistant depression: Focus on vagal nerve stimulation and ketamine. Clin Psychopharmacol Neurosci. 2014. 12: 83-93
108. Sheline YI, West T, Yarashesk KI, Swarm R, Jasielec MS, Fisher JR. An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014. 6: 236re4-
109. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids and traumatic brain injury. Br J Pharmacol. 2011. 163: 1402-10
110. Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis. 2015. 6: e1601-
111. Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol. 2012. 167: 1218-31
112. Stern CAJ, Gazarini L, Vanvossen AC, Zuardi AW, Galve-Roperh I, Guimaraes FS. Delta(9)-tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption. Eur Neuropsychopharmacol. 2015. 25: 958-65
113. Stern CA, Gazarini L, Takahashi RN, Guimarães FS, Bertoglio LJ. On disruption of fear memory by reconsolidation blockade: Evidence from cannabidiol treatment. Neuropsychopharmacology. 2012. 37: 2132-42
114. Uribe-Mariño A, Francisco A, Castiblanco-Urbina MA, Twardowschy A, Salgado-Rohner CJ, Crippa J. Anti-Aversive Effects of Cannabidiol on Innate Fear-Induced Behaviors Evoked by an Ethological Model of Panic Attacks Based on a Prey vs the Wild Snake Epicrates cenchria crassus Confrontation Paradigm. Neuropsychopharmacology. 2012. 37: 412-21
115. Valdeolivas S, Satta V, Pertwee RG, Fernandez-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: Role of CB1 and CB2 receptors. ACS Chem Neurosci. 2012. 3: 400-6
116. Van Der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci. 2006. 63: 1410-24
117. Velenovská M, Fisar Z. Effect of cannabinoids on platelet serotonin uptake. Addict Biol. 2007. 12: 158-66
118. Voth EA. Guidelines for prescribing medical marijuana. West J Med. 2001. 175: 305-6
119. Last accessed on 2018 Jan 29. Available from: https://www.wada-ama.org/sites/default/files/prohibited_list_2018_en.pdf.
120. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004. 10: 434-41
121. Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology. 2006. 185: 524-8
122. Wang Q, Shao F, Wang W. Maternal separation produces alterations of forebrain brain-derived neurotrophic factor expression in differently aged rats. Front Mol Neurosci. 2015. 8: 49-
123. Wee N, Kandiah N, Acharyya S, Chander RJ, Ng A, Au WL. Depression and anxiety are co-morbid but dissociable in mild Parkinson's disease: A prospective longitudinal study of patterns and predictors. Parkinsonism Relat Disord. 2016. 23: 50-6
124. Whalley BJ. Cannabis in the Management and Treatment of Seizures and Epilepsy: A Scientific Review Pre-publication release for public domain dissemination. American Herbal Pharmacopoeia. 2014. p.
125. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signaling at hippocampal synapses. Nature. 2001. 410: 588-92
126. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet. 2003. 362: 1517-26
127. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005. 76: 1664-9
128. Zhang K, Jiang H, Zhang Q, Du J, Wang Y, Zhao M. Brain-derived neurotrophic factor serum levels in heroin-dependent patients after 26 weeks of withdrawal. Compr Psychiatry. 2016. 65: 150-5
129. Zhornitsky S, Potvin S. Cannabidiol in Humans—The Quest for Therapeutic Targets. Pharmaceuticals. 2012. 5: 529-52